Objective: To date, biomarkers are not routinely used in endometrial cancer diagnosis, prognosis, and follow-up. The purpose of this study was to evaluate whether serum HE4 was related to clinicopathological risk factors and outcome. Second, the role of serum HE4 and CA125 was assessed as indicator for recurrent disease during follow-up.
Methods: A total of 174 patients with endometrial cancer between 1999 and 2009 were selected for this retrospective study. Serum HE4 and CA125 were analyzed at primary diagnosis, during follow-up, and at the time of recurrence. Correlations with clinicopathological factors were studied by univariate and multivariate survival analyses. Lead time was calculated in order to determine which serum marker was elevated prior to clinical detection of recurrent disease.
Results: Serum levels of HE4 and CA125 were significantly associated with high tumor grade, myometrial invasion, lymph node involvement, and advanced stage (p < 0.01). HE4 was an independent prognostic factor for reduced disease-free survival and overall survival with hazard ratios of 2.96 (95% confidence interval: 1.18-7.99) and 3.27 (95% confidence interval: 1.18-9.02), respectively. At recurrence, 75% of the patients had an elevated HE4 compared to 54% with an elevated CA125. HE4 levels were more frequently elevated in patients with distant metastasis compared to local recurrences, 67% and 37%, respectively. Serum HE4 detected a recurrence with a median of 126 days earlier than clinical confirmation.
Conclusion: Elevated serum HE4 is an independent risk factor for reduced disease-free survival and overall survival. HE4 seems to be superior to CA125 in the detection of recurrent disease during follow-up, mainly in high-risk endometrial cancer patients who are more prone to distant metastasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1010428318757103 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adjuvant Therapy in Early Uterine Serous Carcinoma.
Am J Epidemiol
January 2025
Division of Gynecologic Oncology, UPMC Magee-Womens Hospital, Pittsburgh PA, USA.
Objective: Uterine serous carcinoma (USC) is a rare diagnosis but associated with high mortality. There is limited data to guide adjuvant treatment decisions in early stage disease. The purpose of this study is to evaluate the impact of adjuvant therapy on recurrence-free survival (RFS) and overall survival (OS) in early stage USC.
View Article and Find Full Text PDFConstruction of cuproptosis-related genes risk model predicts the prognosis of Uterine Corpus Endometrial Carcinoma.
Sci Rep
January 2025
Department of Obstetrics and Gynecology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint, Guangzhou, 510000, China.
Cuproptosis, a recently discovered form of cell death, has emerged as a crucial player in tumor development, although its role in uterine corpus endometrial carcinoma (UCEC) remains inadequately explored. This study aims to identify prognostically relevant cuproptosis-related genes in endometrial cancer. Cuproptosis-related genes were sourced from previously published studies and the FerrDb database.
View Article and Find Full Text PDFPrognostic significance of right subdiaphragmatic washing cytology in patients with endometrial cancer.
Sci Rep
January 2025
Department of Gynecologic Oncology, National Hospital Organization (NHO) Shikoku Cancer Center, Ko-160 Minami-Umemoto, Matsuyama, 7910280, Japan.
Cancer cells in the right subdiaphragmatic lavage may reflect peritoneal dissemination, but its prognostic significance is unknown. This study investigated recurrence-free survival (RFS), overall survival (OS), and recurrence patterns in patients with curatively resected endometrial cancer by cytology collection site. Peritoneal cytology was collected at the beginning of surgery by washing the pelvic and right subdiaphragmatic cavity separately.
View Article and Find Full Text PDFCompressed SENSE acceleration factor influence on magnetic resonance image quality in patients with endometrial cancer.
Phys Med
January 2025
Center for Radiology, University Clinical Center of Vojvodina, Hajduk Veljkova 1-9, 21000 Novi Sad, Serbia; Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovića 3, 21000 Novi Sad, Serbia. Electronic address:
Objectives: To investigate the impact of compressed sensing - sensitivity encoding (CS-SENSE) acceleration factor on the diagnostic performance of magnetic resonance imaging (MRI) within standard female pelvis protocol in patients with endometrial cancer.
Methods: T2-weighted turbo spin echo (TSE) sequence from standard female pelvic MRI protocol was chosen due to its long acquisition time and essential role in the evaluation of morphological characteristics of the female pelvic anatomical structures. Fully sampled reference scans and multiple prospectively 2x to 5x under-sampled CS-SENSE scans were acquired.
Cystic Spaces in the Endometrium on Ultrasound and Correlations With Pathological Diagnosis: A Contemporary Retrospective Cohort Study in a Tertiary Centre.
Aust N Z J Obstet Gynaecol
January 2025
Royal Women's Hospital, Melbourne, Victoria, Australia.
Objectives: To determine the correlation between the ultrasound finding of cystic spaces in the endometrium and endometrial hyperplasia or cancer.
Materials And Methods: We performed a retrospective cohort study at a tertiary teaching hospital in Victoria, Australia, between January 2014 and December 2016. Patients who had a tertiary ultrasound where the endometrium was assessed and underwent endometrial sampling in the subsequent year were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!